Panelists Mark A. Socinski, MD; Jared M. Weiss, MD; John V. Heymach, MD, PhD; and Dean F. Bajorin, MD, outline the emergence and use of PD-L1 inhibitors, atezolizumab, and durvalumab in non–small cell lung cancer.

свернуть